Just as for previous schemes, metrics are being used to track VPAG, the UK’s voluntary scheme that covers branded medicines ...

VPAG is just the latest iteration of agreements struck between the UK government and industry. The minutes note that, whilst ...

Sales of Elevidys are quickly gaining ground on Sarepta's exon-skipping trio, which need to be dosed chronically. In the ...

Ayvakit has been recommended by NICE for ASM – an umbrella term that covers aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm (SM-AHN), and mast cell ...

The Molecular Glue Drug Development Summit returns to Boston with fresh insights and opportunities! With powerhouse ...

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it ...

The 6th RNAi-Based Therapeutics Summit is returning to Boston in January 2025 with fresh insights and perspectives.

The $12.50-per-share takeover has been approved by Avid's board and is scheduled to close in the first quarter of 2025, ...

Boston, US-based XRHealth is leading the deal, acquiring NeuroReality of the Netherlands for an undisclosed sum, combining their products and expertise in the use of XR and virtual reality software ...

Thousands of men in the UK with advanced hormone-sensitive prostate cancer could soon be eligible for an oral therapy – Accord Healthcare's Orgovyx – that can be taken at home rather than ...

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category – but has now decided on a lead candidate. The company said that ...

Roche's PiaSky has been approved by the European Commission, becoming the first therapy for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by monthly subcutaneous ...